Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: NASDAQ CM
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Life Science Equipment

Exact Sciences Corp

+ Add to Watchlist

EXAS:US

24.4400 USD 2.4200 10.99%

As of 20:10:00 ET on 05/04/2015.

Snapshot for Exact Sciences Corp (EXAS)

Open: 23.0100 Day's Range: 22.9900 - 24.8900 Volume: 5,520,976
Previous Close: 22.0200 52wk Range: 10.6900 - 29.9700 1-Yr Rtn: +107.47%

Stock Chart for EXAS

No chart data available.
  • EXAS:US 24.4400
  • 1D
  • 1M
  • 1Y
22.0200
Interactive EXAS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for EXAS

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. SPX -
Earnings Per Share (USD) (ttm) -1.4100
Est. EPS (USD) (12/2015) -1.6310
Est. PEG Ratio -
Market Cap (M USD) 2,173.03
Shares Outstanding (M) 88.91
30 Day Average Volume 1,602,132
Price/Book (mrq) 8.4158
Price/Sale (ttm) 371.0622
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 07/22/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for EXAS

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for EXAS

Exact Sciences Corp., is focused on developing and commercializing a non-invasive molecular screening test for the early detection and prevention of colorectal cancer. The Company's test is a stool-based DNA test that identifies both pre-cancer and cancer by detecting genetic mutations in colorectal cancer cells.

Kevin T ConroyChairman/President/CEOManeesh K AroraSenior VP/COO
Graham P LidgardSenior VP/Chief Science OfcrScott CowardSenior VP/General Counsel
More Company Profile & Key Executives for EXAS

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil